EB1-3 Chain of IL-35 Along With TGF-β Synergistically Regulate Anti-leishmanial Immunity

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2019 Apr 30

PMID 31031744

Citations 10

Authors

Mohammad Asad

Abdus Sabur

Mohammad Shadab

Sonali Das

Mohd Kamran

Nicky Didwania

Nahid Ali

Affiliations

Soon will be listed here.

Abstract

Immunosuppression is a characteristic feature of chronic leishmaniasis. The dynamicity and the functional cross talks of host immune responses during infection are still not clearly understood. Here we explored the functional aspects of accumulation of immune suppressive cellular and cytokine milieu during the progression of murine visceral leishmaniasis. In addition to IL-10 and TGF-β, investigation on the responses of different subunit chains of IL-12 family revealed a progressive elevation of EBI-3 and p35 chains of EBI-3 with infection in BALB/c mice. The expansion of CD25 and FoxP3 positive T cells is associated with loss of IFN-γ and TNF-α response in advanced disease. and neutralization of TGF-β and EBI-3 suggests a synergism in suppression of host anti-leishmanial immunity. The down-regulation of EBI-3 and TGF-β is crucial for re-activation of JAK-STAT pathway for induction as well as restoration of protective immunity against infection.

Citing Articles

Chemokines Signature and T Cell Dynamics in Leishmaniasis: Molecular insight and therapeutic application.

Upadhyay S, Kumar S, Singh V, Tiwari R, Kumar A, Sundar S Expert Rev Mol Med. 2024; 1-55.

PMID: 39587036 PMC: 11707835. DOI: 10.1017/erm.2024.36.

Immunization with recombinant LiHyp1 protein plus adjuvant is protective against tegumentary leishmaniasis.

Jesus M, Lage D, Vale D, Freitas C, Pimenta B, Moreira G Parasitol Res. 2023; 122(12):2917-2931.

PMID: 37768367 DOI: 10.1007/s00436-023-07981-6.

Leishmania donovani Attenuates Dendritic Cell Trafficking to Lymph Nodes by Inhibiting C-Type Lectin Receptor 2 Expression via Transforming Growth Factor-β.

Yadav M, Akhtar M, Mishra M, Kumar S, Kumar R, Shubham Microbiol Spectr. 2023; 11(3):e0412222.

PMID: 37125906 PMC: 10269552. DOI: 10.1128/spectrum.04122-22.

T Lymphocyte Exhaustion During Human and Experimental Visceral Leishmaniasis.

Costa-Madeira J, Trindade G, Almeida P, Silva J, Carregaro V Front Immunol. 2022; 13:835711.

PMID: 35585983 PMC: 9108272. DOI: 10.3389/fimmu.2022.835711.

Network-Based Integrated Analysis of Transcriptomic Studies in Dissecting Gene Signatures for LPS-Induced Acute Lung Injury.

Cao F, Wang C, Long D, Deng Y, Mao K, Zhong H Inflammation. 2021; 44(6):2486-2498.

PMID: 34462829 PMC: 8405180. DOI: 10.1007/s10753-021-01518-8.

References

Mukhopadhyay S, Bhattacharyya S, Majhi R, De T, Naskar K, Majumdar S . Use of an attenuated leishmanial parasite as an immunoprophylactic and immunotherapeutic agent against murine visceral leishmaniasis. Clin Diagn Lab Immunol. 2000; 7(2):233-40. PMC: 95854. DOI: 10.1128/CDLI.7.2.233-240.2000. View

Murray H, Lu C, Mauze S, Freeman S, Moreira A, Kaplan G . Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy. Infect Immun. 2002; 70(11):6284-93. PMC: 130311. DOI: 10.1128/IAI.70.11.6284-6293.2002. View

Wilson M, Recker T, Rodriguez N, Young B, Burnell K, Streit J . The TGF-beta response to Leishmania chagasi in the absence of IL-12. Eur J Immunol. 2003; 32(12):3556-65. DOI: 10.1002/1521-4141(200212)32:12<3556::AID-IMMU3556>3.0.CO;2-Q. View

Tsagozis P, Karagouni E, Dotsika E . Function of CD8+ T lymphocytes in a self-curing mouse model of visceral leishmaniasis. Parasitol Int. 2005; 54(2):139-46. DOI: 10.1016/j.parint.2005.02.005. View

Murray H, Flanders K, Donaldson D, Sypek J, Gotwals P, Liu J . Antagonizing deactivating cytokines to enhance host defense and chemotherapy in experimental visceral leishmaniasis. Infect Immun. 2005; 73(7):3903-11. PMC: 1168607. DOI: 10.1128/IAI.73.7.3903-3911.2005. View

Nylen S, Sacks D . Interleukin-10 and the pathogenesis of human visceral leishmaniasis. Trends Immunol. 2007; 28(9):378-84. DOI: 10.1016/j.it.2007.07.004. View

Niedbala W, Wei X, Cai B, Hueber A, Leung B, McInnes I . IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol. 2007; 37(11):3021-9. DOI: 10.1002/eji.200737810. View

Anderson C, Lira R, Kamhawi S, Belkaid Y, Wynn T, Sacks D . IL-10 and TGF-beta control the establishment of persistent and transmissible infections produced by Leishmania tropica in C57BL/6 mice. J Immunol. 2008; 180(6):4090-7. DOI: 10.4049/jimmunol.180.6.4090. View

Stanley A, Zhou Y, Amante F, Randall L, Haque A, Pellicci D . Activation of invariant NKT cells exacerbates experimental visceral leishmaniasis. PLoS Pathog. 2008; 4(2):e1000028. PMC: 2265425. DOI: 10.1371/journal.ppat.1000028. View

10.

Banerjee A, De M, Ali N . Complete cure of experimental visceral leishmaniasis with amphotericin B in stearylamine-bearing cationic liposomes involves down-regulation of IL-10 and favorable T cell responses. J Immunol. 2008; 181(2):1386-98. DOI: 10.4049/jimmunol.181.2.1386. View

11.

Bhowmick S, Mazumdar T, Ali N . Vaccination route that induces transforming growth factor beta production fails to elicit protective immunity against Leishmania donovani infection. Infect Immun. 2009; 77(4):1514-23. PMC: 2663136. DOI: 10.1128/IAI.01739-07. View

12.

Bhattacharjee S, Gupta G, Bhattacharya P, Adhikari A, Majumdar S, Majumdar S . Anti-iL-10 mAb protection against experimental visceral leishmaniasis via induction of Th1 cytokines and nitric oxide. Indian J Exp Biol. 2009; 47(6):489-97. View

13.

Lin J, Li M, Wang Z, He S, Ma X, Li D . The role of CD4+CD25+ regulatory T cells in macrophage-derived foam-cell formation. J Lipid Res. 2009; 51(5):1208-17. PMC: 2853448. DOI: 10.1194/jlr.D000497. View

14.

Ravindran R, Bhowmick S, Das A, Ali N . Comparison of BCG, MPL and cationic liposome adjuvant systems in leishmanial antigen vaccine formulations against murine visceral leishmaniasis. BMC Microbiol. 2010; 10:181. PMC: 2904331. DOI: 10.1186/1471-2180-10-181. View

15.

Collison L, Chaturvedi V, Henderson A, Giacomin P, Guy C, Bankoti J . IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol. 2010; 11(12):1093-101. PMC: 3008395. DOI: 10.1038/ni.1952. View

16.

Osorio E, Zhao W, Espitia C, Saldarriaga O, Hawel L, Byus C . Progressive visceral leishmaniasis is driven by dominant parasite-induced STAT6 activation and STAT6-dependent host arginase 1 expression. PLoS Pathog. 2012; 8(1):e1002417. PMC: 3261917. DOI: 10.1371/journal.ppat.1002417. View

17.

Vignali D, Kuchroo V . IL-12 family cytokines: immunological playmakers. Nat Immunol. 2012; 13(8):722-8. PMC: 4158817. DOI: 10.1038/ni.2366. View

18.

Owens B, Beattie L, Moore J, Brown N, Mann J, Dalton J . IL-10-producing Th1 cells and disease progression are regulated by distinct CD11c⁺ cell populations during visceral leishmaniasis. PLoS Pathog. 2012; 8(7):e1002827. PMC: 3406093. DOI: 10.1371/journal.ppat.1002827. View

19.

Soong L, Henard C, Melby P . Immunopathogenesis of non-healing American cutaneous leishmaniasis and progressive visceral leishmaniasis. Semin Immunopathol. 2012; 34(6):735-51. PMC: 4111229. DOI: 10.1007/s00281-012-0350-8. View

20.

Wang Z, Liu J, Liu Z, Shen R, Zhang G, Xu J . Tumor-derived IL-35 promotes tumor growth by enhancing myeloid cell accumulation and angiogenesis. J Immunol. 2013; 190(5):2415-23. PMC: 3578001. DOI: 10.4049/jimmunol.1202535. View